BCRX
バイオクリスト・ファーマシューティカルズ
BCRX
バイオクリスト・ファーマシューティカルズ
BioCryst Pharmaceuticals, Inc.'s shares remain under pressure. At the same time, Orladeyo revenue increased 6.7% QoQ to $158.2 million in the second quarter. BioCryst's royalty financing obligations d
BioCryst expects up to $645 million in 2026 sales from its HAE drug Orladeyo, giving it capital to pursue external deals. As large drugmakers prioritize multibillion dollar assets, small and midsize b